|
Lightlake Therapeutics Inc. to discuss with King’s College London’s
Institute of Psychiatry on
the Development of a New Opiate Overdose Treatment
LONDON –January 3, 2012 (Business Wire) -- Lightlake Therapeutics Inc.
(OTCBB:
LLTP - News)
(the “Company” or “Lightlake”),
an early stage biopharmaceutical company developing modern addiction
treatments based on its expertise using opioid antagonists, announced
today that it is seeking to collaborate with
Europe's largest centre for research and post-graduate education in
psychiatry, King’s College London Institute
of Psychiatry, to develop a new treatment for opiate overdose.
Lightlake has agreed to liaise with Professor John Strang, Head of
Addictions at King’s’ Institute
of Psychiatry (IoP) and Director of the National Addiction Centre who
has pioneered the approach of Take-Home Emergency Naloxone to prevent
heroin overdose deaths. It
is now established that there are times of particular risk, such as on
release from prison in the UK, where prisoners with previous heroin
addiction histories are over seven times more likely to suffer a
drug-related death during the first two weeks after their release, and
one in 200 released prisoners in the UK with a history of heroin use die
from a drug-related death within four weeks of re-entering society.
Lightlake hope to develop a new
naloxone spray suitable for heroin overdose resuscitation, and which may
be particularly suitable for administration by a parent or other family
member.
Dr. Roger Crystal, Chief Executive Officer of Lightlake, commented, “We
are honored to work towards partnering with the IoP in a concerted
effort to create a novel treatment for opiate overdose, which is growing
in prevalence worldwide due not only to the availability of street
heroin but also due to the rising dependency on prescribed opioid
painkillers. Recent studies show that heroin-related deaths account for
around eight percent of deaths in individuals between the ages of 15 to
44 in the UK alone.”
About Lightlake Therapeutics, Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical company
aiming to build a platform of biopharmaceutical solutions to common
addictions and related disorders. Currently, the Company is focused on
providing a safe, effective and simple treatment for patients who are
obese or overweight as a result of Binge Eating Disorder in addition to
those patients suffering from Bulimia Nervosa. Lightlake recently
acquired patents that will allow it to widen its product pipeline to
address patients with addictions to opioid painkillers, methadone,
cocaine and amphetamine. The Company anticipates launching a development
program for each of these purposes in the future.
About King’s College London
King's College London is one of the top 30 universities in the world
(2011/12 QS international world rankings), and was The Sunday Times
'University of the Year 2010/11', and the fourth oldest in England. A
research-led university based in the heart of London, King's has nearly
23,500 students (of whom more than 9,000 are graduate students) from
nearly 140 countries, and some 6,000 employees. King's is in the second
phase of a £1 billion redevelopment programme which is transforming its
estate.
King's has an outstanding reputation for providing world-class teaching
and cutting-edge research. In the 2008 Research Assessment Exercise for
British universities, 23 departments were ranked in the top quartile of
British universities; over half of our academic staff work in
departments that are in the top 10 per cent in the UK in their field and
can thus be classed as world leading. The College is in the top seven UK
universities for research earnings and has an overall annual income of
nearly £450 million. Of note, King’s College London’s Institute of Psychiatry is a major contributor to the N-ALIVE study, a randomised trial of take-home Naloxone to prevent heroin overdose deaths post-prison release:
http://www.kcl.ac.uk/iop/depts/addictions/research/drugs/N-ALIVE.aspx
King's has a particularly distinguished reputation in the humanities,
law, the sciences (including a wide range of health areas such as
psychiatry, medicine, nursing and dentistry) and social sciences
including international affairs. It has played a major role in many of
the advances that have shaped modern life, such as the discovery of the
structure of DNA and research that led to the development of radio,
television, mobile phones and radar. It is the largest centre for the
education of healthcare professionals in Europe; no university has more
Medical Research Council Centres. King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are part of King's Health Partners. King's Health Partners Academic Health Sciences Centre (AHSC) is a pioneering global collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts, including leading teaching hospitals and comprehensive mental health services. For more information, visit:
The
College is in the midst of a five-year, £500 million fundraising
campaign – World questions|King’s answers – created to address some of
the most pressing challenges facing humanity as quickly as feasible. The
campaign’s three priority areas are neuroscience and mental health,
leadership and society, and cancer. More information about the campaign
is available at
www.kcl.ac.uk/kingsanswers.
Safe Harbor
This press release contains forward-looking statements. These statements
relate to future events or our future financial performance and involve
known and unknown risks, uncertainties and other factors that may cause
our or our industry's actual results, levels of activity, performance or
achievements to be materially different from any future results, levels
of activity, performance or achievements expressed, implied or inferred
by these forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as "may," "will,"
"should," "could," "would," "expects," "plans," "intends,"
"anticipates," "believes," estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and other
comparable terminology. These statements are only predictions based on
our current expectations and projections about future events. You should
not place undue reliance on these statements. Actual events or results
may differ materially. In evaluating these statements, you should
specifically consider various factors. These and other factors may cause
our actual results to differ materially from any forward- looking
statement. We undertake no obligation to update any of the
forward-looking statements after the date of this presentation to
conform those statements to reflect the occurrence of unanticipated
events, except as required by applicable law.
Investor Contact:
Mr. Kevin Fickle, President
NUWA Group LLC.
Tel: +1-925-330-8315
Email:
kevin@nuwagroup.com
Company Contact:
Dr. Roger Crystal
Lightlake Therapeutics Inc.
Tel: +44(0)-207-034-1943 |